Comparison of ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion

Retina

Volumn 35, Issue 7, 2015, Pages 1393-1400

  Ozkok, Ahmet ^a   Saleh, Omar A ^a,b   Sigford, Douglas K ^a   Heroman, James W ^a   Schaal, Shlomit ^a  

^a University of Louisville School of Medicine   (United States)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; DRUG COMBINATION; DRUG IMPLANT; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADD ON THERAPY; AGE DISTRIBUTION; AGED; APHAKIA; CATARACT; CENTRAL MACULAR THICKNESS; CHRONOTHERAPY; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERVENTION STUDY; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SEX RATIO; STEROID THERAPY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; DRUG IMPLANT; ECONOMICS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL VEIN OCCLUSION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DEXAMETHASONE; DRUG COMBINATIONS; DRUG COSTS; DRUG IMPLANTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84942030887     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/iae.0000000000000475     Document Type: Conference Paper

References (18)

1. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
2. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-1128.
3. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133; e1121.
4. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-2049.
5. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-1602.
6. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012;119: 1024-1032.
7. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-437.
8. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-2460.
9. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146; e1133.
10. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112; e1101.
11. Pielen A, Feltgen N, Isserstedt C, et al. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 2013;8: e78538.
12. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008;115:2199-2205.
13. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-96.
14. Preferences and Trends (PAT) Survey 2013. Available at: https://www.asrs.org/content/documents/-2013asrspatsurveyresults.pdf. Accessed October 22, 2014.
15. Sharareh B, Gallemore R, Taban M, et al. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina 2013;33:1227-1231.
16. Fekrat S, Shea AM, Hammill BG, et al. Resource use and costs of branch and central retinal vein occlusion in the elderly. Curr Med Res Opin 2010;26:223-230.
17. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond) 2011;25:981-988.
18. Taylor M, Serbetci E, Ferreira A, et al. A United Kingdombased economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO). J Med Econ 2014;17:423-434.